CLOVER HEALTH INVESTMENTS, CORP. /DE
For the period ended Mar 31, 2026. Filed May 8, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 8, 2026
CLOV$4.93+2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets at March and December 31,
CONDENSED CONSOLIDATED BALANCE SHEETS
(Dollars in thousands, except share amounts)
| March 31, 2026 | December 31, 2025 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $173,265 | $78,301 |
| Short-term investments | 4,294 | 17,047 |
| Investment securities, available-for-sale (Amortized cost: 2026: $24,216; 2025: $23,231) | 24,190 | 23,131 |
| Investment securities, held-to-maturity (Fair value: 2026: $1,794; 2025: $1,779) | 1,794 | 1,777 |
| Accrued retrospective premiums | 129,215 | 63,875 |
| Healthcare receivables | 73,474 | 94,866 |
| Prepaid expenses | 18,423 | 18,209 |
| Other assets, current | 23,366 | 10,649 |
| Total current assets | 448,021 | 307,855 |
| Investment securities, available-for-sale (Amortized cost: 2026: $202,886; 2025: $186,464) | 202,240 | 187,092 |
| Investment securities, held-to-maturity (Fair value: 2026: $12,300; 2025: $12,495) | 12,444 | 12,571 |
| Property and equipment, net | 6,904 | 6,385 |
| Other intangible assets | 2,990 | 2,990 |
| Other assets, non-current | 25,129 | 24,118 |
| Total assets | $697,728 | $541,011 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Unpaid claims | $260,417 | $153,250 |
| Accounts payable and accrued expenses | 39,170 | 36,211 |
| Accrued salaries and benefits | 31,230 | 16,038 |
| Other liabilities, current | 5,766 | 3,324 |
| Total current liabilities | 336,583 | 208,823 |
| Other liabilities, non-current | 21,719 | 23,484 |
| Total liabilities | 358,302 | 232,307 |
| Commitments and Contingencies (Note 12) | ||
| Stockholders' equity: | ||
| Class A Common Stock, $0.0001 par value; 2,500,000,000 shares authorized at March 31, 2026 and December 31, 2025; 429,555,578 and 426,669,369 issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 43 | 43 |
| Class B Common Stock, $0.0001 par value; 500,000,000 shares authorized at March 31, 2026 and December 31, 2025; 95,715,856 and 92,373,157 issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 9 | 9 |
| Additional paid-in capital | 2,695,144 | 2,682,663 |
| Accumulated other comprehensive (loss) income | (672) | 528 |
| Accumulated deficit | (2,261,018) | (2,288,352) |
| Less: Treasury stock, at cost; 34,977,670 and 33,412,273 shares held at March 31, 2026 and December 31, 2025, respectively | (94,080) | (86,187) |
| Total stockholders' equity | 339,426 | 308,704 |
| Total liabilities and stockholders' equity | $697,728 | $541,011 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.